Bioatla Inc
BCAB0.622USD
-0.069-10.00%
Close 09/19, 16:00（ET）Quotes delayed by 15 min
36.52MMarket Cap
LossP/E TTM
More Details of Bioatla Inc Company
BioAtla, Inc. is a clinical-stage biopharmaceutical company focused on developing antibody-based therapeutics for the treatment of solid tumor cancer. The Company’s product candidates include Mecbotamab vedotin (BA3011), Ozuriftabmab vedotin (BA3021), BA3071, and BA3182. Its lead product candidate, BA3011, is a conditionally active biologics (CAB) antibody-drug conjugates (ADC) that targets AXL, which is a protein kinase receptor. The BA3071 is a potential therapeutic for multiple solid tumor types, including soft tissue and bone sarcoma, and non-small cell lung cancer (NSCLC). BA3021 is developing a CAB antibody drug conjugate directed against a receptor tyrosine kinase such as orphan receptor 2 (ROR2). BA3071 is a CAB anti-CTLA-4 antibody that is being developed as a therapeutic for multiple solid tumor indications. BA3182 is designed with an EpCAM binding domain and a CD3 binding domain, both binding domains with CAB activity (Dual-CAB), for the treatment of advanced adenocarcinoma.
Company Info
Ticker SymbolBCAB
Company nameBioatla Inc
IPO dateDec 16, 2020
CEODr. Jay M. Short, Ph.D.
Number of employees61
Security typeOrdinary Share
Fiscal year-endDec 16
Address11085 Torreyana Road
CitySAN DIEGO
Stock exchangeNASDAQ Global Market Consolidated
CountryUnited States of America
Postal code92121
Phone18585580708
Websitehttps://www.bioatla.com/
Ticker SymbolBCAB
IPO dateDec 16, 2020
CEODr. Jay M. Short, Ph.D.
Company Executives
Name
Name/Position
Position
Shareholding
Change
Dr. Jay M. Short, Ph.D.
Dr. Jay M. Short, Ph.D.
Chairman of the Board, Chief Executive Officer, Co-Founder
Chairman of the Board, Chief Executive Officer, Co-Founder
2.52M
-0.25%
Dr. Eric L. Sievers, M.D.
Dr. Eric L. Sievers, M.D.
Chief Medical Officer
Chief Medical Officer
407.12K
-0.67%
Mr. Richard A. Waldron
Mr. Richard A. Waldron
Chief Financial Officer, Senior Vice President
Chief Financial Officer, Senior Vice President
388.92K
-0.61%
Dr. Lawrence Steinman, M.D.
Dr. Lawrence Steinman, M.D.
Lead Independent Director
Lead Independent Director
144.27K
+19.46%
Dr. Mary Ann Gray, Ph.D.
Dr. Mary Ann Gray, Ph.D.
Independent Director
Independent Director
143.20K
+19.63%
Dr. Susan Moran, M.D.
Dr. Susan Moran, M.D.
Independent Director
Independent Director
118.11K
+24.84%
Mr. Edward L. (Eddie) Williams
Mr. Edward L. (Eddie) Williams
Independent Director
Independent Director
--
--
Mr. Scott A. Smith
Mr. Scott A. Smith
Director
Director
--
--
Ms. Sylvia Mcbrinn
Ms. Sylvia Mcbrinn
Independent Director
Independent Director
--
--
Mr. Christian Vasquez, CPA
Mr. Christian Vasquez, CPA
Chief Accounting Officer, Controller, Corporate Secretary
Chief Accounting Officer, Controller, Corporate Secretary
--
--
Name
Name/Position
Position
Shareholding
Change
Dr. Jay M. Short, Ph.D.
Dr. Jay M. Short, Ph.D.
Chairman of the Board, Chief Executive Officer, Co-Founder
Chairman of the Board, Chief Executive Officer, Co-Founder
2.52M
-0.25%
Dr. Eric L. Sievers, M.D.
Dr. Eric L. Sievers, M.D.
Chief Medical Officer
Chief Medical Officer
407.12K
-0.67%
Mr. Richard A. Waldron
Mr. Richard A. Waldron
Chief Financial Officer, Senior Vice President
Chief Financial Officer, Senior Vice President
388.92K
-0.61%
Dr. Lawrence Steinman, M.D.
Dr. Lawrence Steinman, M.D.
Lead Independent Director
Lead Independent Director
144.27K
+19.46%
Dr. Mary Ann Gray, Ph.D.
Dr. Mary Ann Gray, Ph.D.
Independent Director
Independent Director
143.20K
+19.63%
Dr. Susan Moran, M.D.
Dr. Susan Moran, M.D.
Independent Director
Independent Director
118.11K
+24.84%
Revenue Breakdown
No Data
No Data
By Business
By Region
No Data
Shareholding Stats
Updated: Tue, Aug 19
Updated: Tue, Aug 19
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Acorn Capital Advisors, LLC
8.23%
OPOKA Towarzystwo Funduszy Inwestycyjnych S.A.
6.04%
Short (Jay M)
4.30%
The Vanguard Group, Inc.
3.04%
Acadian Asset Management LLC
2.54%
Other
75.85%
Shareholders
Shareholders
Proportion
Acorn Capital Advisors, LLC
8.23%
OPOKA Towarzystwo Funduszy Inwestycyjnych S.A.
6.04%
Short (Jay M)
4.30%
The Vanguard Group, Inc.
3.04%
Acadian Asset Management LLC
2.54%
Other
75.85%
Shareholder Types
Shareholders
Proportion
Investment Advisor
21.01%
Individual Investor
11.04%
Hedge Fund
4.12%
Investment Advisor/Hedge Fund
3.99%
Research Firm
0.62%
Private Equity
0.02%
Other
59.21%
Institutional Shareholding
Updated: Tue, Jul 1
Updated: Tue, Jul 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q2
222
25.27M
43.26%
-19.66M
2025Q1
236
24.74M
42.74%
-20.20M
2024Q4
263
32.45M
57.22%
-12.96M
2024Q3
259
29.88M
61.37%
-17.19M
2024Q2
266
34.25M
70.95%
-15.78M
2024Q1
275
36.99M
76.93%
-12.58M
2023Q4
283
37.85M
79.00%
-13.74M
2023Q3
290
39.74M
85.24%
-20.01M
2023Q2
294
41.64M
89.42%
-15.48M
2023Q1
295
41.22M
88.67%
-9.50M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Acorn Capital Advisors, LLC
4.84M
8.28%
+803.07K
+19.92%
May 15, 2025
OPOKA Towarzystwo Funduszy Inwestycyjnych S.A.
3.55M
6.07%
+3.55M
--
Mar 06, 2025
Short (Jay M)
2.53M
4.33%
-6.35K
-0.25%
May 31, 2025
The Vanguard Group, Inc.
1.82M
3.11%
-14.47K
-0.79%
Mar 31, 2025
Acadian Asset Management LLC
1.69M
2.89%
+1.53M
+968.91%
Mar 31, 2025
Tang Capital Management, LLC
1.37M
2.35%
--
--
Mar 31, 2025
Short (Carolyn Anderson)
1.35M
2.32%
--
--
Apr 21, 2025
Smith Scott Andrew
852.35K
1.46%
+23.50K
+2.84%
Jun 18, 2025
Renaissance Technologies LLC
744.83K
1.27%
-84.76K
-10.22%
Mar 31, 2025
Aguja Capital GmbH
750.00K
1.28%
--
--
Feb 28, 2025
View more
Related ETFs
Updated: Sat, Sep 6
Updated: Sat, Sep 6
Name
Proportion
ProShares UltraPro Russell2000
0%
ProShares Ultra Nasdaq Biotechnology
0%
ProShares Hedge Replication ETF
0%
Proshares Ultra Russell 2000
0%
iShares Micro-Cap ETF
0%
ProShares UltraPro Russell2000
Proportion0%
ProShares Ultra Nasdaq Biotechnology
Proportion0%
ProShares Hedge Replication ETF
Proportion0%
Proshares Ultra Russell 2000
Proportion0%
iShares Micro-Cap ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
